The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study was the first large-scale, prospective study to examine the benefits ...

The trial will focus on evaluating the safety and tolerability of JOTROL™, Jupiter's patented resveratrol-based therapeutic platform. JOTROL™ is designed to enhance bioavailability and reduce ...

A panelist discusses how treatment strategies for recurrent nasopharyngeal carcinoma (NPC) have evolved, with the updated NCCN guidelines now recommending toripalimab plus gemcitabine/cisplatin as ...

LLC ("Catalent") for the production of JOTROL™ softgel capsules to support Jupiter’s upcoming Phase 2a clinical trial in Parkinson’s disease. Under the terms of the agreement, Catalent will ...

A high resting heart rate is another potential risk factor. In one study, healthy men and women had 18 and 10 percent ...

First three consumer products expected to launch in Q3 2025, providing near-term revenue growthJupiter, Florida, March 04, 2025 (GLOBE ...

Under the terms of the agreement, Zina will provide comprehensive services related to the execution of the exploratory Phase 2a trial evaluating JOTROL TM, Jupiter's patented resveratrol-based ...

In other recent news, Jupiter Neurosciences, Inc. has announced a strategic partnership with Zina Biopharmaceuticals, LLC to advance its Phase 2a clinical trial for Parkinson's disease.

Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner ...